Azra AI and RevealDx Announce Partnership 

Azra AI and RevealDx are teaming up to improve the identification and management of high-risk lung nodules.

This partnership builds upon Azra AI’s recent acquisition of Thynk health, which provides cancer screening and incidental findings management. Customers can now use one integrated solution to identify high-risk nodules, manage these nodules through diagnosis, and seamlessly connect to oncology workflow automation.  

“This partnership strengthens our enterprise-wide intelligence platform,” Azra AI CEO John Marshall said. “The integration of the mSI score into the clinical workflow empowers providers to diagnose patients earlier while increasing clinical efficiency. We are excited to deliver this new technology to our customers because not only are we detecting  lung cancer earlier with RevealDX, but once identified, Azra’s oncology platform will then coordinate the patient’s care all  the way through survivorship.” 

Recently cleared by the U.S. Food and Drug Administration (FDA), the RevealDx technology—marketed as RevealAI-Lung—characterizes incidental lung nodules by producing a score called the Malignancy Similarity Index (mSI). mSI is intended to help radiologists make more informed follow-up recommendations to assist in cancer diagnosis. The company has validated the software on more than 1,500 patients from various cohorts, and RevealAI-Lung is now reimbursable by Medicare using codes 0721T and  0722T. 

“When vendors partner, patients and providers can benefit, and that is certainly the case here,” RevealDx CEO Chris Wood stated. “We are proud of the fact that Azra AI chose to integrate mSI into their clinical workflows and introduce RevealAI-Lung to their installed base. Just producing a malignancy risk score is not sufficient. It needs to be integrated  into platforms built for the full continuum, which is exactly what Azra AI provides.” 

Azra AI is a healthcare enterprise platform that operationalizes underutilized data to optimize and orchestrate care and clinical trial pathways—ensuring patients receive immediate, coordinated care within their health system, increasing patient retention and outcomes, and making patient care visible through actionable real-time reporting. By combining advanced agentic AI, multimodal data integration, and workflow automation, Azra transforms fragmented clinical data into actionable intelligence—powering solutions across lung and breast cancer screening, all incidental findings, multidisciplinary meetings, enterprise patient management/care coordination, clinical trial matching, ED discharge, and robust reporting and analytics. 

Azra’s ability to unify these capabilities within a single platform enables health systems to identify patients earlier,  coordinate care longitudinally, and eliminate gaps across the continuum, according to the company. Deployed across hundreds of health systems, Azra’s platform reduces time to treatment, which delivers measurable improvements in patient outcomes,  operational efficiency, and ROI at scale. 

RevealDx has developed CADx software for characterizing suspicious cancerous lesions. The company has published several studies demonstrating significant improvement in both early cancer detection and reduction in false positives. Studies show that by integrating this patented technology into routine clinical use, healthcare providers can more effectively triage lung nodules. The software is CE-marked (MDR) and cleared by the FDA.